TRILUMINATE随机队列:三尖瓣缘对缘修复治疗重度三尖瓣反流1年结果
TRILUMINATE Pivotal随机对照试验纳入572例有症状重度三尖瓣反流患者,评估TriClip行三尖瓣经导管缘对缘修复(T-TEER)的1年结局;主要复合终点(全因死亡/三尖瓣手术、心衰住院、KCCQ改善)达标(win ratio=1.84,P<0.0001),T-TEER显著降低三尖瓣反流并改善生活质量和6分钟步行距离,但全因死亡或三尖瓣手术率及心衰住院率未降低。
要点
- T-TEER主要复合终点达标(win ratio=1.84,P<0.0001)。
- 30天中度及以下三尖瓣反流达88.9% vs 对照5.3%。
- 1年全因死亡或三尖瓣手术率及心衰住院率未降低。
核心结论
- TriClip在TRILUMINATE Pivotal全随机队列中安全有效,显著降低三尖瓣反流并改善6分钟步行距离和健康状况。
- T-TEER未降低1年内全因死亡或三尖瓣手术率及心衰住院率。
研究设计与样本
- TRILUMINATE Pivotal为国际随机对照试验,评估TriClip行三尖瓣经导管缘对缘修复(T-TEER)用于有症状重度三尖瓣反流患者。
- 2019年8月21日至2022年6月29日随机572例,包括主要队列(n=350)和后续入组(n=222)。
- 主要终点为全因死亡或三尖瓣手术、心衰住院(HFH)和KCCQ生活质量改善的分层复合终点(1年)。
主要发现
- 全队列主要终点达标(win ratio=1.84;P<0.0001)。
- 12个月全因死亡和三尖瓣手术免除率设备组90.6%、对照组89.9%(P=0.82)。
- 年化HFH率设备组与对照组相当(0.17 vs 0.20 events/patient-year;P=0.40)。
- 52.3%设备组患者KCCQ评分改善≥15分,对照组为23.5%(P<0.0001)。
- 30天中度及以下三尖瓣反流设备组88.9% vs 对照5.3%(P<0.0001)。
关键数值与推荐
- 1年KCCQ变化:设备组13.0 ± 1.4分 vs 对照组-0.5 ± 1.4分(P<0.0001)。
- 1年6分钟步行距离变化:设备组1.7 ± 7.5 m vs 对照组-27.4 ± 7.4 m(P<0.0001)。
- T-TEER主要不良事件免除率98.9%,对照性能目标90%(P<0.0001)。
临床怎么用
- 对于有症状重度三尖瓣反流患者,T-TEER可显著降低三尖瓣反流并改善生活质量和运动耐量。
- 不应期望T-TEER在1年内降低全因死亡、三尖瓣手术或心衰住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tricuspid regurgitation (TR) is a right-sided valvular disease independently associated with morbidity and mortality. The TRILUMINATE Pivotal (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is the first randomized controlled trial assessing the impact of TR reduction with tricuspid transcatheter edge-to-edge repair (T-TEER). OBJECTIVES: Outcomes from the full randomized cohort of the TRILUMINATE Pivotal trial have not been previously reported, and the additional enrollment may further support the safety and effectiveness of T-TEER through 1 year. METHODS: The TRILUMINATE Pivotal trial is an international randomized controlled trial of T-TEER with the TriClip device in patients with symptomatic, severe TR. Adaptive trial design allowed enrollment past the primary analysis population. The primary outcome was a hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations (HFHs), and quality-of-life improvement measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year. RESULTS: Between August 21, 2019, and June 29, 2022, 572 subjects were randomized, including the primary cohort (n = 350) and subsequent enrollment (n = 222). Subjects were older (78.1 ± 7.8 years) and predominantly female (58.9%), with atrial fibrillation (87.8%) and prior HFH (23.8%). The primary endpoint was met for the full cohort (win ratio = 1.84; P < 0.0001). Freedom from all-cause mortality and tricuspid valve surgery through 12 months was 90.6% and 89.9% for the device and control groups, respectively (P = 0.82). Annualized HFH rate was comparable between device and control subjects (0.17 vs 0.20 events/patient-year; P = 0.40). A significant treatment effect was observed for change in quality of life with 52.3% of device subjects achieving a ≥15-point KCCQ score improvement (compared with 23.5% of control subjects; P < 0.0001). All secondary endpoints favored T-TEER: moderate or less TR at 30 days (88.9% vs 5.3%; P < 0.0001), KCCQ change at 1 year (13.0 ± 1.4 points vs -0.5 ± 1.4 points; P < 0.0001), and 6-minute walk distance change at 1 year (1.7 ± 7.5 m vs -27.4 ± 7.4 m; P < 0.0001). Freedom from major adverse events was 98.9% for T-TEER (vs performance goal: 90%; P < 0.0001). CONCLUSIONS: TriClip was safe and effective in the full randomized cohort of TRILUMINATE Pivotal with significant TR reduction and improvements in 6-minute walk distance and health status. Rates of all-cause mortality or tricuspid valve surgery and HFH through 1 year were not reduced by T-TEER.
引用
- Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort. J Am Coll Cardiol. 2024. PMID: 39471883. doi:10.1016/j.jacc.2024.10.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。